Biological Sex Influences the Pharmacokinetics and Organ Dosimetry of 177Lu-DOTATATE: A Systematic Preclinical Evaluation
Open Access
- 15 May 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 774
Abstract
Background/Objectives: While 177Lu-DOTATATE has demonstrated clinical efficacy in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs), current dosing regimens do not account for potential sex-based pharmacokinetic differences. Our study systematically characterizes sex-dependent pharmacokinetic variations of 177Lu-DOTATATE in preclinical models to provide the first preclinical evidence base informing future sex-stratified clinical investigations. Methods: Sex-stratified pharmacokinetic and biodistribution studies were conducted in male and female SD rats following intravenous administration of 177Lu-DOTATATE at multiple dose levels: 2.86, 5.71, and 11.43 mCi/kg. Metabolic stability and renal excretion patterns were characterized. Safety assessments included acute toxicity, vascular irritation, hemolysis, and allergenicity testing. Therapeutic efficacy was evaluated exclusively in female AR42J xenograft-bearing CB-17 SCID mice. Results: Significant sex-dependent pharmacokinetic differences were observed at high (11.43 mCi/kg) and low (2.86 mCi/kg) dose levels, with females exhibiting 30–40% higher AUC and Cmax values compared to males (p < 0.05). Both sexes demonstrated preferential accumulation in SSTR-expressing tissues, particularly the pancreas (females: 10.87 ± 2.51% ID/g; males: 9.10 ± 0.76% ID/g) and adrenal glands, with rapid clearance from non-target organs. Radio-HPLC analysis confirmed high metabolic stability with no detectable radiolabeled metabolites, and over 90% of radioactivity was recovered through renal excretion. Safety assessments demonstrated excellent tolerability across dose levels. In female xenograft models, treatment achieved tumor growth inhibition of 92.35–96.44% and 100% survival rate versus 10% in controls, though mid/high doses caused weight loss. Conclusions: Our study provides systematic preclinical evidence of sex-dependent pharmacokinetic differences in 177Lu-DOTATATE, with females demonstrating significantly higher systemic exposure than males at specific dose levels. These findings establish the systematic preclinical evidence base for sex-dependent pharmacokinetic differences in 177Lu-DOTATATE, providing a scientific rationale for incorporating sex as a stratification variable in future dosimetry-guided clinical studies.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (2025-I2M-KJ-018)
- R&D Center of Mednovo Group Co., Ltd, Suzhou, China (MDN002)
This publication has 28 references indexed in Scilit:
- Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) CaseEuropean Journal of Drug Metabolism and Pharmacokinetics, 2023
- Sex and gender perspectives in colorectal cancerESMO Open, 2023
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- 177Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correctionJournal of Applied Clinical Medical Physics, 2020
- Peptide Receptor Radiotherapy: Current Approaches and Future DirectionsCurrent Treatment Options in Oncology, 2019
- Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetryEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Pancreatic neuroendocrine tumors: Challenges in an underestimated diseaseCritical Reviews in Oncology/Hematology, 2016
- Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and courseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011